Moderna to Test Coronavirus Vaccine Booster Shot in New Clinical Trial

The first jab of Moderna's (NASDAQ:MRNA) two-shot coronavirus vaccine hasn't made it into the arms of the millions who will eventually receive it, but the company is already planning to gauge the effectiveness of a booster.

In a presentation at this year's annual J.P. Morgan Healthcare Conference, Moderna said it plans to do so in a clinical trial involving participants of earlier studies of the vaccine, mRNA-1273. It has already begun contacting potential participants, and it plans to begin the study in July.